BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/3/2026 6:28:04 AM | Browse: 2 | Download: 3
 |
Received |
|
2025-08-18 02:31 |
|
Peer-Review Started |
|
2025-08-18 02:31 |
|
First Decision by Editorial Office Director |
|
2025-10-27 09:12 |
|
Return for Revision |
|
2025-10-27 09:12 |
|
Revised |
|
2025-10-28 07:59 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-27 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-27 04:03 |
|
Articles in Press |
|
2025-11-27 04:03 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-26 05:50 |
|
Publish the Manuscript Online |
|
2026-02-03 06:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Shifting paradigm in locally advanced resectable gastric and gastroesophageal junction cancers
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nabil Ismaili |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nabil Ismaili, Associate Professor, Chief Physician, Director, MD, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Health Sciences, Boulevard Mohammed Taieb Naciri, Commune Hay Hassani, Casablanca 20000, Morocco. ismailinabil@yahoo.fr |
| Key Words |
Gastric cancer; Locally advanced; Perioperative therapy; Chemotherapy; Immunotherapy |
| Core Tip |
The recent real-world study by Wang et al adds to the growing evidence that perioperative sintilimab combined with oxaliplatin and S-1 chemotherapy improves pathological response and overall survival in non-metastatic gastric cancer, with a manageable safety profile. However, the conclusions are tempered by the study’s retrospective design, limited power, and the use of a potentially suboptimal chemotherapy backbone. Crucially, this data aligns with the positive results of the large phase III MATTERHORN trial, solidifying the paradigm shift. The collective evidence now strongly suggests that adding immunotherapy to perioperative chemotherapy enhances cure rates for locally advanced resectable gastric and gastroesophageal junction cancers, establishing this combination as a new standard of care. |
| Publish Date |
2026-02-03 06:28 |
| Citation |
Ismaili N. Shifting paradigm in locally advanced resectable gastric and gastroesophageal junction cancers. World J Gastrointest Oncol 2026; 18(2): 113150 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i2/113150.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i2.113150 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
